Biotechnology - Avastin

Filter

Current filters:

Avastin

Popular Filters

Erbitux equal to Avastin in colorectal cancer survival, FIRE-3 study shows

Erbitux equal to Avastin in colorectal cancer survival, FIRE-3 study shows

30-06-2014

Merck Serono, the biotech subsidiary of Germany’s Merck KGaA, has released positive new clinical trial…

AvastinBiotechnologyErbituxMerck KGaAMerck SeronoOncologyResearchRoche

US firms establish strategic partnership around biosimilars

06-08-2013

Privately-held Oncobiologics has formed a broad strategic partnership with fellow USA-based inVentiv…

AvastinBiotechnologyErbituxGenericsHerceptinHumiraImmunologicalsinVentive HealthOncobiologicsOncologyProductionResearchRituxan

Cheaper anti-cancer drug as effective as expensive disease-specific agent in treating wet AMD

21-07-2013

An anti-cancer drug has been proven to be equally as effective in treating the most common cause of blindness…

AvastinBiotechnologyEuropeFinancialLucentisNovartisOphthalmicsPharmaceuticalResearchRoche

Additional indications in Japan for Roche's Avastin and Astellas' Prograf

17-06-2013

Swiss drug major Roche (ROG: SIX) says that the Japanese Ministry of Health, Labor and Welfare (MHLW)…

Asia-PacificAstellas PharmaAvastinBiotechnologyImmunologicalsOncologyPharmaceuticalPrografRegulationRoche

Roche's Avastin extends lives of cervical cancer patients; positive in glioblastoma

03-06-2013

Data presented from the study, known as GOG240, showed that the addition of Swiss pharma major Roche's…

AvastinBiotechnologyGenentechOncologyPharmaceuticalResearchRoche

NICE rejects Avastin for ovarian cancer, but backs Lucentis for RVO

22-05-2013

The UK's drugs watchdog the National Institute for Health and Care Excellence (NICE) has this morning…

AvastinBiotechnologyEuropeLucentisNovartisOncologyOphthalmicsPharmaceuticalPricingRegulationRoche

Should medical compendia hold so much power? Asks GlobalData

10-04-2013

Guidelines for off-label drug use hold immense commercial implications, and stricter controls are needed…

AvastinBiotechnologyNorth AmericaOncologyPharmaceuticalRegulation

Russia's Biocad plans to produce high-tech drugs in Brazil

19-03-2013

Biocad, one of Russia's leading biotechnology companies, plans to launch production of several of its…

AvastinBiocadBiotechnologyGenericsHerceptinMabTheraOncologyProductionRocheSouth America

Italy's antitrust body investigating Roche and Novartis for alleged cartel

21-02-2013

The Italian antitrust authority has opened a cartel investigation of Swiss drug majors Novartis (NOVN:…

AvastinBiotechnologyEuropeGenentechLegalLucentisNovartisOphthalmicsPharmaceuticalRoche

FDA clears new use for Roche's Avastin and Novartis' Exjade

25-01-2013

The US Food and Drug Administration has approved a new use for Swiss drug major Roche's (ROG: SIX) US…

AvastinBiotechnologyExjadeGenentechNorth AmericaNovartisOncologyPharmaceuticalRegulationRoche

UK's NICE says Roche's Avastin not cost effective for advanced ovarian cancer

18-12-2012

The UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has published…

AvastinBiotechnologyEuropeOncologyPharmaceuticalPricingRegulationRoche

San Antonio breast cancer meeting highlights

10-12-2012

There was mixed news coming out of the San Antonio Breast Cancer Symposium (SABCS), which concluded on…

AvastinBiotechnologyEisaiGenentechHerceptinOncologyPerjetaPharmaceuticalResearchRoche

Novartis' Lucentis captures two-thirds of wet-AMD patient share in Europe

28-11-2012

Retinal specialists in the EU5 (France, Germany, Italy, Spain and the UK) treat 66% of intravitreal-pharmaceutically-treated…

AvastinBayerBiotechnologyEuropeEyleaLucentisMarkets & MarketingNovartisOphthalmicsPharmaceuticalRoche

Roche's Avastin effective in people with newly-diagnosed glioblastoma

20-11-2012

Adding Swiss drug major Roche's (ROG: SIX) blockbuster cancer drug Avastin (bevacizumab) to the current…

AvastinBiotechnologyOncologyPharmaceuticalResearchRoche

NICE says Roche's Avastin in breast cancer does not provide enough benefit to justify its cost

21-08-2012

The latest and final guidance from the UK's drug watchdog the National Institute for Health and Clinical…

AvastinBiotechnologyEuropeOncologyPharmaceuticalPricingRegulationRoche

US FDA revokes Roche/Genentech Avastin license for metastatic breast cancer

21-11-2011

After months of deliberations, the US Food and Drug Administration (FDA Commissioner is revoking the…

AvastinBiotechnologyGenentechNorth AmericaOncologyPharmaceuticalRegulationRoche

Parexel

Parexel

Back to top